Skip to main content
Top
Published in: Indian Journal of Surgical Oncology 1/2023

05-08-2022 | Gastrectomy | Original Article

Surgical and Oncological Outcomes after Neoadjuvant Therapy for Non-Metastatic Gastric GISTs

Authors: Amr Abouzid, Ahmed Setit, Ziad Emarah, Mosab Shetiwy

Published in: Indian Journal of Surgical Oncology | Issue 1/2023

Login to get access

Abstract

Surgical resection with negative margins of non-metastatic gastric GISTs is considered the main therapeutic option in GISTs treatment. Neoadjuvant therapy with imatinib is associated with higher response rates in advanced GISTs. We reported 34 patients with non-metastatic gastric GISTs who underwent partial gastrectomy at the Oncology Center, Mansoura University, Egypt, after receiving a daily dose of 400 mg of imatinib as a neoadjuvant treatment in the period between October 2012 and January 2021. Twenty-two cases underwent open partial gastrectomy, and twelve cases had a laparoscopic partial gastrectomy. The median tumor size at diagnosis was 13.5 cm (range 9–26 cm) and the duration of neoadjuvant therapy was 10.91 months (range 4–12 months). Thirty-three patients had a partial response, while one patient showed progression of the disease on neoadjuvant treatment. Adjuvant therapy was conducted in 29 (85.3%) cases. Complications of neoadjuvant treatment were reported in seven cases in the form of gastritis, bleeding per rectum, fatigue, thrombocytopenia, neutropenia, and edema lower limbs. The disease-free survival (DFS) in this study was 34.53 months, and the overall survival (OS) was 37 months. Recurrence developed in two cases, gastric and peritoneal recurrence (25 and 48 months from the initial diagnosis, respectively). We have concluded that neoadjuvant treatment with imatinib for non-metastatic gastric GISTs is a safe and effective method for tumor downsizing and devitalization to allow minimally invasive and/or organ sparing surgery. Moreover, it decreases the risk of intraoperative tumor rupture and relapse, thus improving the oncological outcome of such tumors.
Literature
7.
go back to reference DeMatteo RP, Gold JS, Saran L, Gönen M, Liau KH, Maki RG, Antonescu CR (2008) Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer: Interdiscip Int J Am Cancer Soc 112(3):608–615CrossRef DeMatteo RP, Gold JS, Saran L, Gönen M, Liau KH, Maki RG, Antonescu CR (2008) Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer: Interdiscip Int J Am Cancer Soc 112(3):608–615CrossRef
13.
go back to reference C Yoo, MH Ryu, BW Kang, SK Yoon, BY Ryoo, HM Chang, YK Kang (2010). A cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol 28(9). https://doi.org/10.1200/JCO.2009.26.5785. C Yoo, MH Ryu, BW Kang, SK Yoon, BY Ryoo, HM Chang, YK Kang (2010). A cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol 28(9). https://​doi.​org/​10.​1200/​JCO.​2009.​26.​5785.
20.
21.
23.
go back to reference Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Benjamin RS (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13):1753–1759. https://doi.org/10.1200/JCO.2006.07.3049CrossRefPubMed Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Benjamin RS (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13):1753–1759. https://​doi.​org/​10.​1200/​JCO.​2006.​07.​3049CrossRefPubMed
24.
go back to reference Huss S, Pasternack H, Ihle MA, Merkelbach-Bruse S, Heitkötter B, Hartmann W, Wardelmann E (2017) Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events. Hum Pathol 62:206–214. https://doi.org/10.1016/j.humpathCrossRefPubMed Huss S, Pasternack H, Ihle MA, Merkelbach-Bruse S, Heitkötter B, Hartmann W, Wardelmann E (2017) Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events. Hum Pathol 62:206–214. https://​doi.​org/​10.​1016/​j.​humpathCrossRefPubMed
Metadata
Title
Surgical and Oncological Outcomes after Neoadjuvant Therapy for Non-Metastatic Gastric GISTs
Authors
Amr Abouzid
Ahmed Setit
Ziad Emarah
Mosab Shetiwy
Publication date
05-08-2022
Publisher
Springer India
Published in
Indian Journal of Surgical Oncology / Issue 1/2023
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-022-01611-w

Other articles of this Issue 1/2023

Indian Journal of Surgical Oncology 1/2023 Go to the issue